Emerging psoriasis therapies go head-to-head with marketed drugs
Comparative efficacy data critical for higher uptake since psoriasis is not considered a life-threatening condition
08-May-2014 -
The market for moderate-to-severe plaque psoriasis therapeutics is becoming increasingly competitive with the imminent arrival of three promising new drug classes: interleukin-17(IL-17) inhibitors, a janus kinase (JAK) inhibitor, and a phosphodiesterase-4 (PDE-4) inhibitor, the last two being ...
biopharmaceuticals
inflammatory diseases
inhibitors
+2